These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 2544634)

  • 21. The utility of serum drug level monitoring during therapy with class III antiarrhythmic agents.
    Follath F
    J Cardiovasc Pharmacol; 1992; 20 Suppl 2():S41-3. PubMed ID: 1279308
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum amiodarone and desethylamiodarone concentrations following nasogastric versus oral administration.
    Kotake T; Takada M; Goto T; Komamura K; Kamakura S; Morishita H
    J Clin Pharm Ther; 2006 Jun; 31(3):237-43. PubMed ID: 16789989
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The clinical results of amiodarone in cardiac arrhythmias: optimal dosing.
    Singh BN; Nademanee K; Kannan R; Ikeda N
    Pacing Clin Electrophysiol; 1984 Jan; 7(1):109-24. PubMed ID: 6199755
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical pharmacokinetics of amiodarone.
    Latini R; Tognoni G; Kates RE
    Clin Pharmacokinet; 1984; 9(2):136-56. PubMed ID: 6370540
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antiarrhythmic effect of chronic oral amiodarone treatment in dogs with myocardial infarction and reproducibly inducible sustained ventricular arrhythmias.
    Abdollah H; Brien JF; Brennan FJ
    J Cardiovasc Pharmacol; 1990 May; 15(5):799-807. PubMed ID: 1692941
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics and pharmacodynamic effects of amiodarone in plasma of ponies after single intravenous administration.
    Trachsel D; Tschudi P; Portier CJ; Kuhn M; Thormann W; Scholtysik G; Mevissen M
    Toxicol Appl Pharmacol; 2004 Feb; 195(1):113-25. PubMed ID: 14962511
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term pretreatment with desethylamiodarone (DEA) or amiodarone (AMIO) protects against coronary artery occlusion induced ventricular arrhythmias in conscious rats.
    Morvay N; Baczkó I; Sztojkov-Ivanov A; Falkay G; Papp JG; Varró A; Leprán I
    Can J Physiol Pharmacol; 2015 Sep; 93(9):773-7. PubMed ID: 26176275
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Potentially significant drug interactions of class III antiarrhythmic drugs.
    Yamreudeewong W; DeBisschop M; Martin LG; Lower DL
    Drug Saf; 2003; 26(6):421-38. PubMed ID: 12688833
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Resting, and rate-dependent depression of Vmax of guinea-pig ventricular action potentials by amiodarone and desethylamiodarone.
    Pallandi RT; Campbell TJ
    Br J Pharmacol; 1987 Sep; 92(1):97-103. PubMed ID: 3664094
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of intravenous amiodarone in the management of cardiac arrhythmias.
    Desai AD; Chun S; Sung RJ
    Ann Intern Med; 1997 Aug; 127(4):294-303. PubMed ID: 9265430
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of the pharmacokinetics and bioavailability of intravenously and orally administered amiodarone in horses.
    De Clercq D; Baert K; Croubels S; van Loon G; Maes A; Tavernier R; Deprez P; De Backer P
    Am J Vet Res; 2006 Mar; 67(3):448-54. PubMed ID: 16506906
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antiarrhythmic effect of desethylamiodarone in conscious rats.
    Varró A; Bódi I; Rabloczky G
    J Pharm Pharmacol; 1987 Jun; 39(6):483-4. PubMed ID: 2886609
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Peripheral neutrophil inclusions in amiodarone treated patients.
    Adams PC; Sloan P; Morley AR; Holt DW
    Br J Clin Pharmacol; 1986 Dec; 22(6):736-8. PubMed ID: 3032227
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Distribution of amiodarone and desethylamiodarone in a patient with acute myocardial infarction after intravenous administration.
    Barbieri E; Latini R; D'Aranno V; Fabbri A; Zampieri P; Trevi GP; Zardini P
    Clin Cardiol; 1987 Nov; 10(11):674-6. PubMed ID: 3677501
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics and body distribution of amiodarone and desethylamiodarone in rats after intravenous administration.
    Plomp TA; Wiersinga WM; van Rossum JM; Maes RA
    In Vivo; 1989; 3(1):33-47. PubMed ID: 2519831
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics, antiarrhythmic effects, and tissue concentrations of amiodarone and desethylamiodarone in dogs with acute coronary artery occlusion.
    Somani P; Simon VA; McManus K
    Can J Cardiol; 1985 Jan; 1(1):56-65. PubMed ID: 3850764
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Drug combinations and interactions with class III agents.
    Marcus FI
    J Cardiovasc Pharmacol; 1992; 20 Suppl 2():S70-4. PubMed ID: 1279312
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Class III antiarrhythmic drugs].
    Aiba T; Kamakura S
    Nihon Rinsho; 1996 Aug; 54(8):2125-31. PubMed ID: 8810787
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Physiologically Based Pharmacokinetic Model of Amiodarone and its Metabolite Desethylamiodarone in Rats: Pooled Analysis of Published Data.
    Lu JT; Cai Y; Chen F; Jia WW; Hu ZY; Zhao YS
    Eur J Drug Metab Pharmacokinet; 2016 Dec; 41(6):689-703. PubMed ID: 26254911
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hemodynamic effects of antiarrhythmic compounds: intrinsic effects and autonomic modulation.
    Hoffmeister HM; Beyer ME; Seipel L
    Am J Cardiol; 1997 Oct; 80(8A):24G-30G. PubMed ID: 9354409
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.